Eintrag weiter verarbeiten
Targeting NAMPT as a therapeutic strategy against stroke
Gespeichert in:
| Zeitschriftentitel: | Stroke and Vascular Neurology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Stroke and Vascular Neurology, 4, 2019, 2, S. 83-89 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
BMJ
|
| Schlagwörter: |
| author_facet |
Wang, Shu-Na Miao, Chao-Yu Wang, Shu-Na Miao, Chao-Yu |
|---|---|
| author |
Wang, Shu-Na Miao, Chao-Yu |
| spellingShingle |
Wang, Shu-Na Miao, Chao-Yu Stroke and Vascular Neurology Targeting NAMPT as a therapeutic strategy against stroke Cardiology and Cardiovascular Medicine Neurology (clinical) |
| author_sort |
wang, shu-na |
| spelling |
Wang, Shu-Na Miao, Chao-Yu 2059-8688 2059-8696 BMJ Cardiology and Cardiovascular Medicine Neurology (clinical) http://dx.doi.org/10.1136/svn-2018-000199 <jats:p>Stroke is the second and the leading most common cause of death in the world and China, respectively, but with few effective therapies. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme for nicotinamide adenine dinucleotide (NAD) salvage synthesis in mammals, thereby influencing NAD-dependent enzymes and constituting a strong endogenous defence system against various stresses. Accumulating in-vitro and in-vivo studies have demonstrated the neuroprotective effect of NAMPT in stroke. Here, we review the direct evidence of NAMPT as a promising target against stroke from five potential therapeutic strategies, including NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product nicotinamide mononucleotide (NMN), and NMN precursors nicotinamide riboside and nicotinamide, and describe the relevant mechanisms and limitations, providing a promising choice for developing novel and effective therapeutic interventions against ischaemic and haemorrhagic stroke.</jats:p> Targeting NAMPT as a therapeutic strategy against stroke Stroke and Vascular Neurology |
| doi_str_mv |
10.1136/svn-2018-000199 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9zdm4tMjAxOC0wMDAxOTk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9zdm4tMjAxOC0wMDAxOTk |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
| imprint |
BMJ, 2019 |
| imprint_str_mv |
BMJ, 2019 |
| issn |
2059-8688 2059-8696 |
| issn_str_mv |
2059-8688 2059-8696 |
| language |
English |
| mega_collection |
BMJ (CrossRef) |
| match_str |
wang2019targetingnamptasatherapeuticstrategyagainststroke |
| publishDateSort |
2019 |
| publisher |
BMJ |
| recordtype |
ai |
| record_format |
ai |
| series |
Stroke and Vascular Neurology |
| source_id |
49 |
| title |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_unstemmed |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_full |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_fullStr |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_full_unstemmed |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_short |
Targeting NAMPT as a therapeutic strategy against stroke |
| title_sort |
targeting nampt as a therapeutic strategy against stroke |
| topic |
Cardiology and Cardiovascular Medicine Neurology (clinical) |
| url |
http://dx.doi.org/10.1136/svn-2018-000199 |
| publishDate |
2019 |
| physical |
83-89 |
| description |
<jats:p>Stroke is the second and the leading most common cause of death in the world and China, respectively, but with few effective therapies. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme for nicotinamide adenine dinucleotide (NAD) salvage synthesis in mammals, thereby influencing NAD-dependent enzymes and constituting a strong endogenous defence system against various stresses. Accumulating in-vitro and in-vivo studies have demonstrated the neuroprotective effect of NAMPT in stroke. Here, we review the direct evidence of NAMPT as a promising target against stroke from five potential therapeutic strategies, including NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product nicotinamide mononucleotide (NMN), and NMN precursors nicotinamide riboside and nicotinamide, and describe the relevant mechanisms and limitations, providing a promising choice for developing novel and effective therapeutic interventions against ischaemic and haemorrhagic stroke.</jats:p> |
| container_issue |
2 |
| container_start_page |
83 |
| container_title |
Stroke and Vascular Neurology |
| container_volume |
4 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792345630542135303 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:26:32.588Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Targeting+NAMPT+as+a+therapeutic+strategy+against+stroke&rft.date=2019-06-01&genre=article&issn=2059-8696&volume=4&issue=2&spage=83&epage=89&pages=83-89&jtitle=Stroke+and+Vascular+Neurology&atitle=Targeting+NAMPT+as+a+therapeutic+strategy+against+stroke&aulast=Miao&aufirst=Chao-Yu&rft_id=info%3Adoi%2F10.1136%2Fsvn-2018-000199&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792345630542135303 |
| author | Wang, Shu-Na, Miao, Chao-Yu |
| author_facet | Wang, Shu-Na, Miao, Chao-Yu, Wang, Shu-Na, Miao, Chao-Yu |
| author_sort | wang, shu-na |
| container_issue | 2 |
| container_start_page | 83 |
| container_title | Stroke and Vascular Neurology |
| container_volume | 4 |
| description | <jats:p>Stroke is the second and the leading most common cause of death in the world and China, respectively, but with few effective therapies. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme for nicotinamide adenine dinucleotide (NAD) salvage synthesis in mammals, thereby influencing NAD-dependent enzymes and constituting a strong endogenous defence system against various stresses. Accumulating in-vitro and in-vivo studies have demonstrated the neuroprotective effect of NAMPT in stroke. Here, we review the direct evidence of NAMPT as a promising target against stroke from five potential therapeutic strategies, including NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product nicotinamide mononucleotide (NMN), and NMN precursors nicotinamide riboside and nicotinamide, and describe the relevant mechanisms and limitations, providing a promising choice for developing novel and effective therapeutic interventions against ischaemic and haemorrhagic stroke.</jats:p> |
| doi_str_mv | 10.1136/svn-2018-000199 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEzNi9zdm4tMjAxOC0wMDAxOTk |
| imprint | BMJ, 2019 |
| imprint_str_mv | BMJ, 2019 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
| issn | 2059-8688, 2059-8696 |
| issn_str_mv | 2059-8688, 2059-8696 |
| language | English |
| last_indexed | 2024-03-01T17:26:32.588Z |
| match_str | wang2019targetingnamptasatherapeuticstrategyagainststroke |
| mega_collection | BMJ (CrossRef) |
| physical | 83-89 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | BMJ |
| record_format | ai |
| recordtype | ai |
| series | Stroke and Vascular Neurology |
| source_id | 49 |
| spelling | Wang, Shu-Na Miao, Chao-Yu 2059-8688 2059-8696 BMJ Cardiology and Cardiovascular Medicine Neurology (clinical) http://dx.doi.org/10.1136/svn-2018-000199 <jats:p>Stroke is the second and the leading most common cause of death in the world and China, respectively, but with few effective therapies. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme for nicotinamide adenine dinucleotide (NAD) salvage synthesis in mammals, thereby influencing NAD-dependent enzymes and constituting a strong endogenous defence system against various stresses. Accumulating in-vitro and in-vivo studies have demonstrated the neuroprotective effect of NAMPT in stroke. Here, we review the direct evidence of NAMPT as a promising target against stroke from five potential therapeutic strategies, including NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product nicotinamide mononucleotide (NMN), and NMN precursors nicotinamide riboside and nicotinamide, and describe the relevant mechanisms and limitations, providing a promising choice for developing novel and effective therapeutic interventions against ischaemic and haemorrhagic stroke.</jats:p> Targeting NAMPT as a therapeutic strategy against stroke Stroke and Vascular Neurology |
| spellingShingle | Wang, Shu-Na, Miao, Chao-Yu, Stroke and Vascular Neurology, Targeting NAMPT as a therapeutic strategy against stroke, Cardiology and Cardiovascular Medicine, Neurology (clinical) |
| title | Targeting NAMPT as a therapeutic strategy against stroke |
| title_full | Targeting NAMPT as a therapeutic strategy against stroke |
| title_fullStr | Targeting NAMPT as a therapeutic strategy against stroke |
| title_full_unstemmed | Targeting NAMPT as a therapeutic strategy against stroke |
| title_short | Targeting NAMPT as a therapeutic strategy against stroke |
| title_sort | targeting nampt as a therapeutic strategy against stroke |
| title_unstemmed | Targeting NAMPT as a therapeutic strategy against stroke |
| topic | Cardiology and Cardiovascular Medicine, Neurology (clinical) |
| url | http://dx.doi.org/10.1136/svn-2018-000199 |